Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling.

Torre C, Wang SJ, Xia W, Bourguignon LY.

Arch Otolaryngol Head Neck Surg. 2010 May;136(5):493-501. doi: 10.1001/archoto.2010.25.

2.
3.

Hyaluronan-CD44 promotes phospholipase C-mediated Ca2+ signaling and cisplatin resistance in head and neck cancer.

Wang SJ, Bourguignon LY.

Arch Otolaryngol Head Neck Surg. 2006 Jan;132(1):19-24.

PMID:
16415424
4.

The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.

Wang SJ, Peyrollier K, Bourguignon LY.

Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):281-8.

PMID:
17372087
7.

Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.

Wang SJ, Bourguignon LY.

Am J Pathol. 2011 Mar;178(3):956-63. doi: 10.1016/j.ajpath.2010.11.077. Review.

8.

Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells.

Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K.

Oncogene. 2012 Jan 12;31(2):149-60. doi: 10.1038/onc.2011.222. Epub 2011 Jun 20.

9.

Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation.

Gouëffic Y, Guilluy C, Guérin P, Patra P, Pacaud P, Loirand G.

Cardiovasc Res. 2006 Nov 1;72(2):339-48. Epub 2006 Jul 29.

PMID:
16934786
10.

Role of hyaluronan synthase 2 to promote CD44-dependent oral cavity squamous cell carcinoma progression.

Wang SJ, Earle C, Wong G, Bourguignon LY.

Head Neck. 2013 Apr;35(4):511-20. doi: 10.1002/hed.22991. Epub 2012 Mar 31.

PMID:
22473523
11.

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R.

Cancer Res. 2009 Apr 1;69(7):3021-31. doi: 10.1158/0008-5472.CAN-08-2881. Epub 2009 Mar 24.

12.
13.

Selective matrix (hyaluronan) interaction with CD44 and RhoGTPase signaling promotes keratinocyte functions and overcomes age-related epidermal dysfunction.

Bourguignon LY, Wong G, Xia W, Man MQ, Holleran WM, Elias PM.

J Dermatol Sci. 2013 Oct;72(1):32-44. doi: 10.1016/j.jdermsci.2013.05.003. Epub 2013 Jun 5.

14.
15.

Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin.

Fetz V, Bier C, Habtemichael N, Schuon R, Schweitzer A, Kunkel M, Engels K, Kovács AF, Schneider S, Mann W, Stauber RH, Knauer SK.

Int J Cancer. 2009 May 1;124(9):2033-41. doi: 10.1002/ijc.24182.

18.
19.

Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression.

Bourguignon LY.

Semin Cancer Biol. 2008 Aug;18(4):251-9. doi: 10.1016/j.semcancer.2008.03.007. Epub 2008 Mar 26. Review.

20.

CD44 variant isoforms in head and neck squamous cell carcinoma progression.

Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY.

Laryngoscope. 2009 Aug;119(8):1518-30. doi: 10.1002/lary.20506.

Supplemental Content

Support Center